In cell based assay the IC50 for inhibition of proliferation of a number of cancer lines was <1 μM, which suggests that mechanisms in addition to RSK1 CTKD inhibition are important for its efficacy as the in vitro Kd is higher than the cell based IC50 (Lowe et al., 2014; Wooten et al., 2022). The gene discussed is RPS6KA1; the disease is cancer.